Compass Therapeutics, Inc.

Compass Therapeutics, Inc.'s Board of Directors approved the adoption of Second Amended and Restated Bylaws, effective June 22, 2026. These new bylaws amend the existing ones to establish exclusive jurisdiction in the United States District Courts for the District of Delaware and District of Massachusetts for resolving any claims arising under the Securities Act of 1933. This update supersedes the company's previous bylaws dated July 17, 2020.

Compass Therapeutics, Inc. announced its participation in two investor events during May 2026. The company will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, and the 2026 Stifel Virtual Targeted Oncology Forum on May 20, 2026. Management will be available for one-on-one meetings at both events, and presentations will be archived online.

Compass Therapeutics announced positive Phase 2/3 study results for Tovecimig in biliary tract cancer, meeting its primary endpoint of overall response rate and showing significant improvement in progression-free survival. The company also received Orphan Drug Designation from the FDA for Tovecimig in BTC. For Q1 2026, Compass Therapeutics reported a net loss of $18.3 million, an increase from $16.6 million in Q1 2025, with cash and marketable securities of $195 million expected to fund operations into 2028.

Compass Therapeutics reported positive Phase 2/3 data for tovecimig in biliary tract cancer, demonstrating statistically significant improvement in progression-free survival and overall response rate, with plans for a BLA submission later this year. The company also provided updates on its pipeline, including an upcoming ASCO presentation for CTX-8371 and the initiation of a Phase 1 study for CTX-10726. For Q1 2026, Compass reported a net loss of $18.3 million and held $195 million in cash and marketable securities, providing a cash runway into 2028.

Compass Therapeutics reported a Q1 2026 net loss of $18.3 million and provided a corporate update. The company announced positive Phase 2/3 data for tovecimig in biliary tract cancer, including statistically significant improvement in progression-free survival and signals of a survival benefit, and plans to submit a Biologics License Application (BLA) later this year. Additionally, the Phase 1 study for CTX-8371 will be presented at ASCO 2026, and initial data for CTX-10726 is expected in Q4 2026. The company holds $195 million in cash, expected to fund operations into 2028.

Compass Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026, at 9:00 a.m. Eastern Time. Stockholders will vote on the election of two Class III directors, the ratification of CohnReznick LLP as the independent auditor for 2026, and advisory votes on executive compensation and its frequency. The company also highlighted recent executive appointments, including Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer in January 2026.

Compass Therapeutics announced positive results from its COMPANION-002 study for tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel for biliary tract cancer. The study met its key secondary endpoint, demonstrating a statistically significant improvement in median progression-free survival (PFS) of 4.7 months versus 2.6 months for paclitaxel alone, representing a 56% reduction in progression risk. The previously announced primary endpoint of overall response rate (ORR) was also met, with 17.1% for the combination versus 5.3% for paclitaxel alone. While overall survival (OS) did not meet statistical significance due to high patient crossover (54%) to the tovecimig arm, a subset analysis showed crossover patients had a median OS of 12.8 months versus 6.1 months for non-crossover patients. The company plans to meet with the FDA for a Biologics License Application (BLA) submission.

Compass Therapeutics announced detailed data from its COMPANION-002 Phase 2/3 study of tovecimig plus paclitaxel in biliary tract cancer (BTC). The study met its primary endpoint with an overall response rate (ORR) of 17.1% for the combination versus 5.3% for paclitaxel alone. Tovecimig also showed a statistically significant improvement in median Progression-Free Survival (PFS) of 4.7 months compared to 2.6 months. While the Overall Survival (OS) endpoint was not met in the ITT analysis due to high patient crossover, post-hoc analysis showed significant OS improvement in crossover patients. The company plans to meet with the FDA for a BLA submission.

Compass Therapeutics, Inc. announced it will host a webcast on Monday, April 27, 2026, at 8:00 AM ET. The event will review topline secondary endpoints from its Phase 2/3 COMPANION-002 clinical study. This study evaluates tovecimig in combination with paclitaxel for patients with advanced biliary tract cancer, providing an important update on their clinical pipeline.